ORPHA:457485
Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome
Also known as: MINDS syndrome · Smith-Kingsmore syndrome
Publications
262,815
Trials
0
Interventional, condition-specific
Researchers
943
Distinct authors in sample
Gene link
MTOR
Definitive
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare multiple anomalies/ syndrome with , characterized by macrocephaly, , , facial features (including tall forehead, downslanting palpebral fissures, hypertelorism, depressed nasal bridge, and macrostomia), megalencephaly, and small thorax. Other reported features are umbilical hernia, muscular , global , autistic behavior, and café-au-lait spots, among others.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0014716
- OMIM:616638
- UMLS:C4225259
Additional Mondo synonyms (1)
Smith-Kingsmore Syndrome
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Definitive — MTOR
- LiteraturePresent
262,815 matched papers (205,752 in last 10 years) Source
- Phenotype characterisedPresent
86 HPO annotations (e.g. Strabismus; Megalencephaly; Perisylvian polymicrogyria) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (MTOR).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
86
Associated phenotypes · MONDO:0014716
- Strabismus
- Megalencephaly
- Perisylvian polymicrogyria
- Large for gestational age
- Short chin
Showing 5 of 86 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
262,815
262,815 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
262,815 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
205,752 in the last 10 years · low confidence
Phrase hits: 82 · MeSH hits: 0
Who's working on it?
943
Distinct author names in 82 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Krueger DA7 papers · 2025
Division of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Papers in Europe PMC - 02Li F4 papers · 2024
Department of Prenatal Diagnostic Center, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, Guangdong, China.
Papers in Europe PMC - 03Liu AC4 papers · 2026
Department of Physiology and Aging, University of Florida College of Medicine, Gainesville, FL 32610, USA. Electronic address: andrew.liu@ufl.edu.
Papers in Europe PMC - 04Prada CE4 papers · 2026
Divisions of Human Genetics, Neurology, Immunobiology, Pediatric Otolaryngology, and Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA; Division of Genetics, Genomics & Metabolism, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL 60611, USA; Department of Pediatrics, Feinberg School of Medicine of Northwestern University, Chicago, IL 60611, USA. Electronic address: cprada@luriechildrens.org.
Papers in Europe PMC - 05Sahin M4 papers · 2025
Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Papers in Europe PMC - 06Tatton-Brown K4 papers · 2025
South West Thames Regional Genomics Service, St George's University Hospitals NHS Foundation Trust, London, UK.
Papers in Europe PMC - 07Baple EL3 papers · 2025
College of Medicine and Health, University of Exeter, Exeter, UK
Papers in Europe PMC - 08Bebin EM3 papers · 2025
University of Alabama at Birmingham, Department of Neurology, Epilepsy Division, Birmingham, Alabama, USA.
Papers in Europe PMC - 09Chen G3 papers · 2024
Department of Prenatal Diagnostic Center, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, Guangdong, China.
Papers in Europe PMC - 10He H3 papers · 2026
Department of Physiology and Aging, University of Florida College of Medicine, Gainesville, FL 32610, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name. 1 observational study did — shown below because natural-history and cohort work can be an important step toward a trial.
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
low confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT04395495·RECRUITING·RASopathy Biorepository
Conditions: RAS Mutation · Neurofibromatosis 1 · Noonan Syndrome · Noonan Syndrome With Multiple Lentigines·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 6 · after dedupe 6 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 6 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (6)
- isrctn·ISRCTN62546421·Recruiting·The European registry of familial pancreatic cancer and hereditary pancreatitis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN72589181·Recruiting·A study to evaluate preventive treatments for talquetamab-related oral toxicity
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN74178658·No longer recruiting·A study comparing talquetamab plus pomalidomide, talquetamab plus teclistamab, and elotuzumab, pomalidomide, and dexamethasone or pomalidomide, bortezomib, and dexamethasone in participants with relapsed or refractory myeloma who have received an Anti-CD38 antibody and lenalidomide
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN57482371·No longer recruiting·Weight loss, urogynaecology symptoms and psychological changes study
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN71978064·No longer recruiting·A trial evaluating active outpatient management to prevent hospital admission in women having fertility treatment who develop ovarian hyperstimulation syndrome
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12622538·No longer recruiting·Family intervention for Sub Saharan African and Caribbean people with psychosis trial
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome" OR "MINDS syndrome" OR "Smith-Kingsmore syndrome") OR ("MTOR" OR "MTOR syndrome" OR "MTOR-related")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome" OR "MINDS syndrome" OR "Smith-Kingsmore syndrome"
Study-type breakdown: 0 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (262815) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-27T16:51:47.755Z
